EDN1 and prostate adenocarcinoma: Considering these results, we suggest using endothelin-1 expression as a complementary option in assessment and report of prostate needle biopsies in prostate adenocarcinoma to help the physician to make the best decision for affected patients, decrease mortality and morbidity by preventing less appropriate radical prostatectomy in aggressive tumors and also selecting patients for endothelin-1 blockade therapy.